Stryker Corporation $SYK Shares Sold by Americana Partners LLC

Americana Partners LLC lessened its holdings in Stryker Corporation (NYSE:SYK) by 4.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,757 shares of the medical technology company’s stock after selling 200 shares during the quarter. Americana Partners LLC’s holdings in Stryker were worth $1,882,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the business. Vanguard Group Inc. grew its holdings in Stryker by 1.1% during the first quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock worth $12,306,572,000 after acquiring an additional 361,136 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Stryker by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after acquiring an additional 1,021,496 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Stryker by 13.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock worth $838,640,000 after purchasing an additional 261,058 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Stryker by 4.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,086,960 shares of the medical technology company’s stock worth $776,871,000 after purchasing an additional 83,954 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Stryker by 1.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,015,374 shares of the medical technology company’s stock worth $750,223,000 after purchasing an additional 30,329 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Price Performance

SYK stock opened at $355.03 on Tuesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The stock’s 50 day moving average price is $373.91 and its 200 day moving average price is $381.34. The firm has a market cap of $135.77 billion, a P/E ratio of 47.02, a PEG ratio of 2.66 and a beta of 0.94. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.13 by $0.06. The business had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the business earned $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, sell-side analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SYK has been the subject of several recent analyst reports. BTIG Research raised their price objective on shares of Stryker from $408.00 to $410.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Truist Financial reaffirmed a “hold” rating and issued a $392.00 target price (down from $407.00) on shares of Stryker in a report on Monday, November 3rd. Evercore ISI decreased their price target on Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a research note on Friday, October 31st. Rothschild & Co Redburn assumed coverage on Stryker in a research note on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price objective for the company. Finally, Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Thirteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $433.37.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 276,173 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the transaction, the director owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. The trade was a 9.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Viju Menon sold 500 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. The trade was a 3.84% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 520,500 shares of company stock worth $184,803,065. 5.90% of the stock is owned by insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.